AstraZeneca reports strong results boosted by promising trials
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
FiercePharma11h
Quantoom, DNA Script and EVA Pharma unite on Africa mRNA project
While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...
GSK launches $2.5 billion buyback, lifts sales target after stellar Q4
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
in-cumbria.com18h
End of an era for pharmaceutical giant GSK
A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...
Why GSK plc (GSK) Went Up on Wednesday
The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...
Hosted on MSN23h
GSK stays optimistic on vaccines amidst US and China woes
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...